Overdose Reversal Drug Now OTC: Saves Lives, Lowers Costs

The Food and Drug Administration (FDA) announced on Tuesday the approval of a third over-the-counter (OTC) version of naloxone nasal spray. This significant development aims to save lives and reduce the financial burden associated with opioid overdoses.

The newly approved Rextovy, a 4-milligram naloxone nasal spray, is now available for direct purchase by consumers. The FDA stated that having multiple approved OTC formulations encourages market competition, potentially leading to lower costs and increased availability through various retail channels.

Naloxone is a vital medication that can counteract the effects of an opioid overdose when administered promptly. The FDA highlighted that empowering individuals without medical training to act swiftly with these products has a proven track record of saving lives.

The number of overdose deaths has seen a notable decrease since the initial FDA approval of an OTC naloxone nasal spray in 2023. However, drug overdose remains a critical public health issue in the U.S., largely fueled by synthetic opioids like illicit fentanyl. Federal figures indicate a substantial decline in overdose fatalities between August 2023 and December 2025.

The product is deemed safe for use even if it's unclear whether opioids are involved. Its packaging includes clear, step-by-step visual instructions, emphasizing the importance of calling 911 after administering the first dose.